Agoracom: Small Cap Investment - Mosaic ImmunoEngineering Inc. - Re: New Pacer--SECOND SUPPLEMENTAL JOINT CASE MANAGEMENT CONFERENCE STATEMENT

Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Reply New Message

Back To Forum List View

New Pacer--SECOND SUPPLEMENTAL JOINT CASE MANAGEMENT CONFERENCE STATEMENT

wolfpackvolt

Nov 04, 2009 01:56AM

gcduck

Rank: President [?]

Points: 12254 [?]

Votes: 135 Score: 3.3 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: New Pacer--SECOND SUPPLEMENTAL JOINT CASE MANAGEMENT CONFERENCE STATEMENT

in response to

New Pacer--SECOND SUPPLEMENTAL JOINT CASE MANAGEMENT CONFERENCE STATEMENT

wolfpackvolt

posted on Nov 04, 2009 04:41AM

Thank your very much, Wolf!

As I see it an additional stay for 90 days is probable and that settlement THIS year is not realistic (and I had hoped for a nice christmas present...;-)):

"Defendants agree that an additional 90-day stay would be beneficial to allow the PTO to finish publishing the Reissue Certificate for the ’336 Patent. Defendants expect that the publication of the Reissue Certificate may facilitate settlement negotiations among the parties. "

GLTA

1 Recommendations

Re: New Pacer--SECOND SUPPLEMENTAL JOINT CASE MANAGEMENT CONFERENCE STATEMENT

DesignGuy

Nov 04, 2009 05:29AM

Re: New Pacer--SECOND SUPPLEMENTAL JOINT CASE MANAGEMENT CONFERENCE STATEMENT

drbtmde

Nov 04, 2009 05:40AM

reexam = good thing

ur2lurking

Nov 04, 2009 07:16AM

Re: reexam = good thing...Indeed, good news in both cases 584/336 patent